Editing Diarrhea (section)

===Other diseases===
Diarrhea can be caused by other diseases and conditions, namely:
* Chronic [[ethanol]] ingestion<ref name="Harrison">{{cite book | vauthors = Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL | title = Harrison's Principles of Internal Medicine | location = New York | publisher = McGraw-Hill | date = 2005 | isbn = 978-0-07-139140-5 | title-link = Harrison's Principles of Internal Medicine }}</ref>
* [[Hyperthyroidism]]<ref name="pmid26576135">{{cite journal | vauthors = Lee KJ | title = Pharmacologic Agents for Chronic Diarrhea | journal = Intestinal Research | volume = 13 | issue = 4 | pages = 306–12 | date = October 2015 | pmid = 26576135 | pmc = 4641856 | doi = 10.5217/ir.2015.13.4.306 }}</ref>
* Certain medications<ref name="pmid26576135"/>
* [[Bile acid malabsorption]]<ref name="pmid26576135"/>
* [[Ischemia|Ischemic]] bowel disease: This usually affects older people and can be due to blocked arteries.
* [[Microscopic colitis]], a type of [[inflammatory bowel disease]] where changes are seen only on histological examination of colonic biopsies.
* [[Bile salt malabsorption]] ([[primary bile acid diarrhea]]) where excessive [[bile acids]] in the [[Colon (anatomy)|colon]] produce a secretory diarrhea.
* Hormone-secreting tumors: some hormones, e.g. [[serotonin]], can cause diarrhea if secreted in excess (usually from a tumor).
* Chronic mild diarrhea in infants and toddlers may occur with no obvious cause and with no other ill effects; this condition is called [[toddler's diarrhea]].
* [[Environmental enteropathy]]
* [[Radiation enteropathy]] following treatment for pelvic and abdominal cancers.
* [[Mast cell activation syndrome]] (MCAS)<ref>{{Cite journal |last1=Afrin |first1=Lawrence B. |last2=Self |first2=Sally |last3=Menk |first3=Jeremiah |last4=Lazarchick |first4=John |date=2016-12-16 |title=Characterization of Mast Cell Activation Syndrome |journal=The American Journal of the Medical Sciences |language=en |volume=353 |issue=3 |pages=207–215 |doi=10.1016/j.amjms.2016.12.013 |pmid=28262205 |pmc=5341697 }}</ref><ref>{{Cite journal |last1=Molderings |first1=Gerhard J. |last2=Haenisch |first2=Britta |last3=Brettner |first3=Stefan |last4=Homann |first4=Jürgen |last5=Menzen |first5=Markus |last6=Dumoulin |first6=Franz Ludwig |last7=Panse |first7=Jens |last8=Butterfield |first8=Joseph |last9=Afrin |first9=Lawrence B. |date=2016 |title=Pharmacological treatment options for mast cell activation disease |journal=Naunyn-Schmiedeberg's Archives of Pharmacology |language=en |volume=389 |issue=7 |pages=671–694 |doi=10.1007/s00210-016-1247-1 |pmid=27132234 |pmc=4903110 }}</ref><ref>{{Cite journal |last1=Valent |first1=Peter |last2=Akin |first2=Cem |last3=Nedoszytko |first3=Boguslaw |last4=Bonadonna |first4=Patrizia |last5=Hartmann |first5=Karin |last6=Niedoszytko |first6=Marek |last7=Brockow |first7=Knut |last8=Siebenhaar |first8=Frank |last9=Triggiani |first9=Massimo |last10=Arock |first10=Michel |last11=Romantowski |first11=Jan |last12=Górska |first12=Aleksandra |last13=Schwartz |first13=Lawrence B. |last14=Metcalfe |first14=Dean D. |date=2020-11-27 |title=Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine |journal=International Journal of Molecular Sciences |language=en |volume=21 |issue=23 |page=9030 |doi=10.3390/ijms21239030 |doi-access=free |pmid=33261124 |pmc=7731385 }}</ref>